Skip to main content
. Author manuscript; available in PMC: 2017 Sep 27.
Published in final edited form as: Oncogene. 2017 Mar 27;36(30):4299–4310. doi: 10.1038/onc.2017.64

Figure 7. Schematic illustration of Skp2’s interaction with Twist to induce progression and chemoresistance of CPRC.

Figure 7

In conditions of low Skp2 levels, β-TrCP ubiquitinates Twist leading to its proteasomal degradation, wherein with high levels of Skp2, Twist is stabilized and activated through ubiquitination by Skp2 allowing for CRPC progression.